/ /

Mark L. Dlugoss, Group Content Director, Ophthalmology Times
Glaucoma 360 expands its ‘horizons’ with new program, sessions
Over the years, Glaucoma 360 has brought the concept of innovation in glaucoma to the forefront. This year’s meeting will surpass the Glaucoma Research Foundation’s (GRF) own “Horizons” by adding a few more “degrees” to its 360-degree concept.
Introducing: Modern Retina
Introducing: Modern Retina
Ophthalmology Times is pleased to introduce a new clinical and educational platform for retina specialists called Modern Retina.
Glaucoma 360 reaches milestones in search of glaucoma cure
The 2016 Glaucoma 360 features a year of major milestones for the three-day meeting as the Glaucoma Research Foundation (GRF) honors leaders in philanthropy, business, and medicine. This year’s Glaucoma 360 marks milestones for all three segments of the event. The “New Horizons Forum,” the centerpiece of Glaucoma 360, registers its 5th anniversary; the “Glaucoma 360 Annual Gala” posts its 10th anniversary; and the Glaucoma Symposium CME will highlight its 20th year in presenting the latest clinical advancements in glaucoma.
Shire committed to ophthalmic space as dry eye drug emerges on FDA horizon
Robert Dempsey, vice president and business unit head at Shire Pharmaceutical’s Ophthalmics Business Unit, recently talked with Ophthalmology Times Group Content Director Mark L. Dlugoss about Shire’s entry into the eye care market. Among the topics discussed are Shire’s attraction to the market, Lifitegrast–its potential dry eye drug, and other potential ophthalmic compounds.
GRF presents Catalyst, Visionary Awards to leaders in medicine, science
Glaucoma Research Foundation (GRF) honored a long-time global leader in ophthalmology with its Catalyst Award on Thursday night at the foundation’s Glaucoma 360 Annual Gala and presented two renowned stem-cell researchers with its Visionary Award.
Glaucoma 360 unites ophthalmic teams in one direction for better solution, ultimately a cure
Glaucoma 360 is an all-encompassing event in which clinicians, scientists, industry, and business converge in one direction to discover a cure for glaucoma.
Andras Komaromy, PhD, wins Shaffer Award for research of gene therapy to control IOP
For his efforts to prove that gene therapy could one day provide lasting control of IOP in patients with glaucoma with known genetic defects, Andras M. Komáromy, PhD, DVM, was awarded the 2015 Shaffer Prize for Innovative Glaucoma Research.
Actavis-Allergan deal seen as ‘marriage of 2 great companies’
Actavis-Allergan deal seen as ‘marriage of 2 great companies’
In November, Actavis announced it was acquiring Allergan in a $66 billion acquisition, thus thwarting a 7-month effort by Valeant Pharmaceuticals.
Editor’s Blog: IOLs again grab the attention at ESCRS
The European Society of Cataract and Refractive Surgeons (ESCRS) never fails to entice ophthalmology with cutting-edge technology, and the XXXII Congress in London has not disappointed attendees. This year’s congress has displayed a wide range of new technologies from cataract and refractive platforms to diagnostic units to surgical instruments. From all the equipment presented, IOL advances have again captured the attention of attendees.
Editor’s Blog: Forget the future, diabetes is an epidemic now
As part of Ophthalmology Times’ coverage of the 14th EURETINA Congress in London this week, Group Content Director Mark L. Dlugoss writes this blog.


View Results